TRACKER 6 OCT 2026 · WADA publishes the 2027 Prohibited List, in force January 1, 2027. What changed
plainly graded.

Tesamorelin

Also called "Egrifta"
FDA approved, one useWADA S2 · prohibited at all times
STATUS AS OF
FDA: approved as Egrifta for excess abdominal fat in HIV-associated lipodystrophy only · WADA: prohibited at all times under the 2026 WADA List (S2.2.4, growth hormone releasing factors) · tracker entry

The short answer: Tesamorelin is a lab-made version of growth-hormone-releasing hormone. As of October 17, 2026 it is FDA-approved for one use only, reducing excess belly fat in people with HIV-associated lipodystrophy, and it is prohibited in sport at all times under the 2026 WADA List.

Written by Maren Holt 2 PUBLIC SOURCES · UPDATED 17 OCT 2026 · NO TIES TO SELLERS
How we source

We collect and compare information from public, cited sources. We cannot guarantee that it is complete, current or correct. This is not medical advice. Only a doctor can prescribe, and a doctor should confirm anything you read here before you act on it.

Based on public sources; we cannot guarantee it is correct. Not medical advice. A doctor should prescribe and confirm. Full disclaimer

What is Tesamorelin?

Growth-hormone-releasing peptide approved for one use. Full section still to be written.

What is Tesamorelin claimed to do, and what does the evidence show?

Overall gradeApproved
Strongest evidenceRandomized trials
UseClaimedShownGrade
Abdominal fat in HIV-associated lipodystrophy Reduces belly fat Approved by the FDA for this use only. Other uses marketed online have not been approved.[1] Approved
Abdominal fat in HIV-associated lipodystrophyApproved
Claimed: Reduces belly fat Shown: Approved by the FDA for this use only. Other uses marketed online have not been approved.[1]

What are the known risks and side effects of Tesamorelin?

The approved label lists the known side effects and warnings. We link to it rather than restate it.

Who should be especially careful
  • People who are pregnant, trying to get pregnant or breastfeeding. There is no human data in pregnancy.
  • Anyone under 18. It has not been studied in young people.
  • Tested athletes and service members. Check with USADA or your service's rules first. A positive test counts whatever the label said.
  • People taking prescription medicines. Interactions have not been studied. Bring the product label to your clinician.
Get medical help now if you have
  • Swelling of the face, lips or throat, trouble breathing, chest pain, a racing heart or fainting. Call 911.
  • Redness spreading from an injection site, warmth, pus or a fever. Get same-day care.
  • Unsure what you took or whether a reaction is serious: Poison Control 1-800-222-1222 (free, 24 hours).
  • Thoughts of harming yourself: call or text 988.

Is Tesamorelin banned in sport?

Prohibited at all times under the 2026 WADA List (S2.2.4, growth hormone releasing factors).[2] Anti-doping rules work on strict liability: a positive test counts whatever the label said.

What don't we know about Tesamorelin?

Still unknown
  • Effects in the off-label uses it is marketed for online.
Why this page has no dosing We don't publish doses, schedules or mixing instructions for Tesamorelin or any unapproved peptide. No human dose has been established for most of these uses, so we list what to ask a licensed prescriber instead. Here's why, and who can legally answer

What should you tell your doctor if you're using Tesamorelin?

Tell them exactly what you took, for how long, and where it came from, and bring the label. These questions can help the conversation:

  • Is there an approved treatment for my goal that has been tested in people?
  • What should I watch for, and which symptoms mean I should stop and call you?
  • Could it interact with the medicines I already take?

Compare next

Sermorelin
Sources
  1. DailyMed / US Food and Drug Administration. Egrifta (tesamorelin) prescribing information .
  2. World Anti-Doping Agency. 2026 Prohibited List (sections S0 and S2) , 2026-01-01.
Changelog
17 OCT 2026 Draft. Statuses read from the regulatory record dated 2026-10-17.
Spotted an error? Report it. We never change a page's updated date without changing its content.